Medical Groups Back Invokana, Other SGLT2 Inhibitors, As FDA Continues Ketoacidosis Review

Published on October 28, 2015 by Sandy Liebhard

Text-Size:A A A+

 

Two prominent medical groups have decided to back continued use of Invokana and other SGLT2 inhibitors, even as federal regulators investigate a possible connection between the medications and diabetic ketoacidosis. Following a clinical review conducted last week in Dallas, Texas, the American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) determined that the prevalence of this potentially life-threatening complication is infrequent, and that the benefits of SGLT2 inhibitors continue to outweigh their risks.

However, the groups did note that the diagnosis of diabetic ketoacidosis if often missed or delayed in patients taking SGLT2 inhibitors, and encouraged the pharmaceutical industry, medical societies and other stakeholders to initiate educational activities to instruct healthcare professionals involved in the management of diabetes on the proper way to identify and treat diabetic ketoacidosis.

In addition to Invokana, other SGLT2 inhibitors include Invokamet, Jardiance, Farxiga, Xigduo XR, and Glyxambi. The medications are indicated to lower blood sugar in adults with Type 2 diabetes. The safety and efficacy of these medications has not been established in patients with Type 1 diabetes, and the U.S. Food & Drug Administration (FDA) has not approved them for use in these patients.

FDA Diabetic Ketoacidosis Investigation

In May, the FDA announced it was investigating 20 cases of diabetic ketoacidosis reported in SGLT2 inhibitor patients between March 2013 and June 2014. Additional incidents had been reported since then. The FDA is trying to determine if these events warrant any changes to the drugs’ prescribing information.

The FDA’s alert noted a number of aspects associated with these cases that could delay the diagnosis of ketoacidosis in patients taking SGLT2 inhibitors. The condition most often presents in patients with Type 1 diabetes, but many of the cases reported to the FDA involved patients taking SGLT2 inhibitors for Type 2 diabetes. Diabetic ketoacidosis is usually associated with high blood glucose levels, but SGLT2 patients who develop this complication may exhibit lower-than-anticipated levels.

Invokana Lawsuit Reviews Now Available

Type 2 diabetics who were diagnosed with ketoacidosis while using Invokana or another SGLT2 inhibitor may be entitled to compensation for medical bills and other damages. To obtain a free, no-obligation Invokana lawsuit review, please contact the nationwide law firm of Bernstein Liebhard LLP at .

Web Analytics